Dev

Glucocerebrosidase mutations in Parkinson disease:molecular pathogenesis,and the basis for personalised therapy with small molecule chaperones Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

UK Dementias Platform Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders 2016    

Manipulating mitochondrial dynamics as a potential therapeutic strategy for Parkinson’s disease Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

New humanised mouse models for dissecting the pathobiology of disease, using FUS-ALS as a paradigm Investments > €500k United Kingdom Motor neurone diseases 2016    

Targeting the innate immune system in Huntington’s disease Investments > €500k United Kingdom Huntington’s disease 2016    

Improving function in Huntington’s disease through neurofeedback: using real-time fMRI to enhance cortical plasticity in early stages of the disease Investments > €500k United Kingdom Huntington’s disease 2016    

MRC Centre for Neuropsychiatric Genetics and Genomics Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders 2016    

Machinery and Mechanisms of Endosomal Protein Sorting – A key Pathway Associated with Alzheimer Disease Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Roles of protein SUMOylation in AMPA receptor trafficking, synaptic dysfunction and cognitive impairment in dementia Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

DJ-1 and neurodegeneration: its roles in mitochondria and in protein misfolding Investments > €500k United Kingdom Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016